Related Experiment Video
Updated: Oct 30, 2025
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
14.4K
Pulmonary Hypertension: Diagnosis and Management
1Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center for Postgraduate Medical Education, ECZ-Otwock, 05-400 Otwock, Poland.
Diagnostics (Basel, Switzerland)
|July 2, 2021
Summary
This special issue focuses on diagnosing and treating pulmonary hypertension (PH). It covers the latest advancements and clinical insights for managing this complex cardiovascular condition.
Area of Science:
- Cardiology
- Pulmonology
- Medical Diagnostics
Background:
- Pulmonary Hypertension (PH) is a severe condition impacting lung vasculature.
- Accurate diagnosis and timely treatment are crucial for patient outcomes.
- This special issue addresses current challenges in PH management.
Discussion:
- Explores novel diagnostic tools and biomarkers for early PH detection.
- Reviews current therapeutic strategies, including pharmacological and non-pharmacological interventions.
- Discusses the importance of a multidisciplinary approach in PH care.
Key Insights:
- Highlights recent breakthroughs in understanding PH pathophysiology.
- Emphasizes the need for personalized treatment algorithms based on PH subtype.
- Showcases advancements in imaging and hemodynamic assessment.
Outlook:
- Predicts future trends in PH research and clinical practice.
- Addresses unmet needs in PH treatment and patient monitoring.
- Encourages further investigation into rare forms of pulmonary hypertension.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
358
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
358
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
295
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
295
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
295
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
295
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
398
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
398
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
287
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
287
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
79
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
79